{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:18Z","timestamp":1740147738040,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11739-024-03571-1","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:01:25Z","timestamp":1709776885000},"page":"599-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities"],"prefix":"10.1007","volume":"19","author":[{"given":"Giorgio","family":"Gentile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahid","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erberto","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-0702","authenticated-orcid":false,"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"3","key":"3571_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B et al (2021) Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23(3):352\u2013380","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"3571_CR2","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G et al (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u20133287","journal-title":"Cardiovasc Res"},{"issue":"6","key":"3571_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs J (2021) Heart failure drug treatment: the fantastic four. Eur Heart J 42(6):681\u2013683","journal-title":"Eur Heart J"},{"issue":"10244","key":"3571_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M et al (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244):121\u2013128","journal-title":"Lancet"},{"key":"3571_CR5","doi-asserted-by":"publisher","unstructured":"De Nicola L et al (2023) Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors. Intern Emerg Med. https:\/\/doi.org\/10.1007\/s11739-023-03427-0","DOI":"10.1007\/s11739-023-03427-0"},{"key":"3571_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.resuscitation.2015.07.017","volume":"95","author":"A Truhlar","year":"2015","unstructured":"Truhlar A et al (2015) European resuscitation council guidelines for resuscitation 2015: section 4. Cardiac arrest in special circumstances. Resuscitation 95:148\u2013201","journal-title":"Resuscitation"},{"issue":"2","key":"3571_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ et al (2022) Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis 80(2):164-173 e1","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 3","key":"3571_CR8","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","volume":"34","author":"RW Hunter","year":"2019","unstructured":"Hunter RW, Bailey MA (2019) Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant 34(Suppl 3):iii2\u2013iii11","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3571_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","volume":"96","author":"BF Palmer","year":"2021","unstructured":"Palmer BF et al (2021) Clinical management of hyperkalemia. Mayo Clin Proc 96(3):744\u2013762","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"3571_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/archinte.141.1.30","volume":"141","author":"S Tan","year":"1981","unstructured":"Tan S, Burton M (1981) Hyporeninemic hypoaldosteronism. An overlooked cause of hyperkalemia. Arch Internal Med 141(1):30\u201333","journal-title":"Arch Internal Med"},{"issue":"703","key":"3571_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/pgmj.60.703.370","volume":"60","author":"D Large","year":"1984","unstructured":"Large D et al (1984) Hyperkalaemia in diabetes mellitus\u2014potential hazards of coexisting hyporeninaemic hypoaldosteronism. Postgrad Med J 60(703):370\u2013373","journal-title":"Postgrad Med J"},{"key":"3571_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5935\/0101-2800.20170086","volume":"39","author":"CHPRT Bello","year":"2017","unstructured":"Bello CHPRT, Duarte JS, Vasconcelos C (2017) Diabetes mellitus and hyperkalemic renal tubular acidosis: case reports and literature review. Brazil J Nephrol 39:481\u2013485","journal-title":"Brazil J Nephrol"},{"issue":"19","key":"3571_CR13","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL et al (2022) Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145(19):1460\u20131470","journal-title":"Circulation"},{"issue":"4","key":"3571_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","volume":"9","author":"L Shen","year":"2021","unstructured":"Shen L et al (2021) Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail 9(4):254\u2013264","journal-title":"JACC Heart Fail"},{"issue":"23","key":"3571_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"6","key":"3571_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2023.04.015","volume":"82","author":"RB Albakr","year":"2023","unstructured":"Albakr RB, Sridhar VS, Cherney DZI (2023) Novel therapies in diabetic kidney disease and risk of hyperkalemia: a review of the evidence from clinical trials. Am J Kidney Dis 82(6):737\u2013742","journal-title":"Am J Kidney Dis"},{"key":"3571_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2021.100635","volume":"95","author":"DB Shrestha","year":"2021","unstructured":"Shrestha DB et al (2021) Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res Clin Exp 95:100635","journal-title":"Curr Ther Res Clin Exp"},{"issue":"7","key":"3571_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B et al (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32(7):820\u2013828","journal-title":"Eur Heart J"},{"issue":"5","key":"3571_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s10557-020-07134-2","volume":"35","author":"Y Zhang","year":"2021","unstructured":"Zhang Y et al (2021) Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis. Cardiovasc Drugs Ther 35(5):1057\u20131066","journal-title":"Cardiovasc Drugs Ther"},{"issue":"23","key":"3571_CR20","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.3390\/jcm10235523","volume":"10","author":"T Imamura","year":"2021","unstructured":"Imamura T et al (2021) Clinical implications of sodium zirconium cyclosilicate therapy in patients with systolic heart failure and hyperkalemia. J Clin Med 10(23):5523","journal-title":"J Clin Med"},{"issue":"1","key":"3571_CR21","first-page":"54","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F et al (2020) Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail 7(1):54\u201364","journal-title":"ESC Heart Fail"},{"issue":"9","key":"3571_CR22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/clc.23683","volume":"44","author":"A Oshima","year":"2021","unstructured":"Oshima A et al (2021) Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate. Clin Cardiol 44(9):1272\u20131275","journal-title":"Clin Cardiol"},{"issue":"6","key":"3571_CR23","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","volume":"40","author":"A Agiro","year":"2023","unstructured":"Agiro A et al (2023) Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study. Adv Ther 40(6):2886\u20132901","journal-title":"Adv Ther"},{"issue":"11","key":"3571_CR24","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1007\/s12325-023-02631-w","volume":"40","author":"JP Dwyer","year":"2023","unstructured":"Dwyer JP et al (2023) Impact of sodium zirconium cyclosilicate plus renin-angiotensin-aldosterone system inhibitor therapy on short-term medical costs in hyperkalemia: OPTIMIZE II real-world study. Adv Ther 40(11):4777\u20134791","journal-title":"Adv Ther"},{"issue":"2","key":"3571_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","volume":"10","author":"JC Tardif","year":"2023","unstructured":"Tardif JC et al (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail 10(2):1066\u20131076","journal-title":"ESC Heart Fail"},{"issue":"Supplement_A","key":"3571_CR26","doi-asserted-by":"publisher","first-page":"A28","DOI":"10.1093\/eurheartj\/suy035","volume":"21","author":"GM Rosano","year":"2019","unstructured":"Rosano GM, Spoletini I, Agewall S (2019) Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. Eur Heart J Suppl 21(Supplement_A):A28\u2013A33","journal-title":"Eur Heart J Suppl"},{"issue":"4","key":"3571_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s11897-009-0037-1","volume":"6","author":"AS Desai","year":"2009","unstructured":"Desai AS (2009) Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 6(4):272\u2013280","journal-title":"Curr Heart Fail Rep"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T06:16:53Z","timestamp":1713853013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3571"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03571-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"17 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/financial disclosures"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}